{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:14:23Z","timestamp":1767676463445,"version":"3.48.0"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017694","name":"Hermann und Lilly Schilling-Stiftung f\u00fcr Medizinische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["VIP+"],"award-info":[{"award-number":["VIP+"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-TR-128"],"award-info":[{"award-number":["CRC-TR-128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-TR-355"],"award-info":[{"award-number":["CRC-TR-355"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1080"],"award-info":[{"award-number":["SFB 1080"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-1292"],"award-info":[{"award-number":["SFB CRC-1292"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immunotherapies are integral in managing multiple sclerosis (MS) and related demyelinating diseases, but adverse drug reactions significantly affect the tolerability of disease-modifying therapies (DMTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aims to assess the safety profile of DMTs within a real-world cohort affected by MS and related diseases and to identify atypical adverse events (AEs) and those of exceptional severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 3850 patients with MS, neuromyelitis optica spectrum disorder (NMOSD), and related conditions (2009\u20132022). Demographic and clinical data were analyzed for patients treated with DMTs. Parameters included prior treatments, AEs, treatment durations, and reasons for discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the cohort, 1989 patients (71.1% female) with a median follow-up of 46.3\u2009months during DMT use were included. Monotherapy was employed in 987 patients, while 1002 received sequential DMTs, totaling 3850 treatments. Adverse reactions led to discontinuation in 24.2% of cases, while disease progression accounted for 22.9%. Among 1878 AEs, 31 (1.7%) were atypical, and 59 (3.1%) were unusually severe, which was systematically categorized based on type, timing, and remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Within the confines of this real-world study, DMT administration emerged as generally well tolerated in MS, related demyelinating diseases and NMOSD. The identification of a limited number of atypical AEs, nevertheless, broadens the spectrum of potential complications associated with DMTs. Although weaker evidence for causal associations between drug exposure and observed AEs remains a limitation in observational studies without comparable control groups, this study underscores the value of real-world investigations in offering insights into the long-term safety of DMTs, particularly for rare events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251320206","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:18:53Z","timestamp":1743769133000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder"],"prefix":"10.1177","volume":"18","author":[{"given":"Amelie","family":"Kirschbaum","sequence":"first","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-4199","authenticated-orcid":false,"given":"Felix","family":"Luessi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arda","family":"Civelek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3655","authenticated-orcid":false,"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Piepgras","sequence":"additional","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-1928","authenticated-orcid":false,"given":"Frauke","family":"Zipp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211039648"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2014.915742"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2007.07.001"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510391344"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0528-1"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(03)00036-6"},{"issue":"3","key":"e_1_3_5_11_2","article-title":"Comparison of first-line and second-line use of fingolimod in relapsing MS: the open-label EARLIMS study","volume":"6","author":"Fern\u00e1ndez O","year":"2020","unstructured":"Fern\u00e1ndez O, Izquierdo G, Aguera E, et al. Comparison of first-line and second-line use of fingolimod in relapsing MS: the open-label EARLIMS study. Mult Scler J Exp Transl Clin 2020; 6(3): 2055217320957358.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000449"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30069-3"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103350"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa127"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-05988-y"},{"issue":"2","key":"e_1_3_5_18_2","first-page":"247","article-title":"Long-term safety and tolerability of glatiramer acetate 20 mg\/ml in the treatment of relapsing forms of multiple sclerosis","volume":"16","author":"Ziemssen T","year":"2017","unstructured":"Ziemssen T, Ashtamker N, Rubinchick S, et al. Long-term safety and tolerability of glatiramer acetate 20 mg\/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf 2017; 16(2): 247\u2013255.","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513519839"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515618020"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019872192"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000335064"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.03.008"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12676"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2013.09.027"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.10.1416-a"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0432-0"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.50802.x"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412463090"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000218"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1506-0"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-65"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.11.008"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12549"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.08.005"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000661"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1730"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.13.2.124"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.032"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123132"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231846"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.01.001"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133279"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102124"},{"issue":"11","key":"e_1_3_5_46_2","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis","volume":"11","author":"Tramacere I","year":"2023","unstructured":"Tramacere I, Virgili G, Perduca V, et al. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2023; 11(11): CD012186.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251320206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251320206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251320206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:05:29Z","timestamp":1767675929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251320206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":45,"alternative-id":["10.1177\/17562864251320206"],"URL":"https:\/\/doi.org\/10.1177\/17562864251320206","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"type":"print","value":"1756-2864"},{"type":"electronic","value":"1756-2864"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"17562864251320206"}}